Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21675599 | 0.77 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL22166482 | 0.75 | RXRA (0.34) | ALDH1A1RXRAGRIN1GRIN2B | |
| SCHEMBL23558267 | 0.74 | SLC6A2 (0.35) | ALDH1A1ESR1ESR2 | |
| SCHEMBL19646227 | 0.73 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL18427396 | 0.73 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL29332958 | 0.72 | RXRA (0.32) | RXRAGRIN1GRIN2B | |
| SCHEMBL21450061 | 0.70 | ESR1 (0.39) | ESR1ESR2 | |
| SCHEMBL23790646 | 0.70 | CXCR4 (0.36) | ALDH1A1RXRAGRIN1GRIN2B | |
| SCHEMBL19954875 | 0.68 | SMN1; SMN2 (0.38) | ALDH1A1 | |
| SCHEMBL11399098 | 0.68 | CCR1 (0.48) | ALDH1A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364255-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-03-28 | — | — | US | disclosed |
| US-9975882-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-9815822-B2 | — | — | 2017-11-14 | — | — | US | disclosed |
| US-9745267-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745297-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | ALDH1A1 3537/4885ESR1 1636/4885ESR2 2260/4885 |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | ALDH1A1 3537/4885ESR1 1636/4885ESR2 2260/4885 |
| US-10364255-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, UGT2B7 | ALDH1A1 583/4885ESR1 841/4885ESR2 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.